Positive outcomes associated with stem cell transplantation in pediatric/AYA patients who receive FLAG-IDA-venetoclax for high-risk AML (ASH 2025) - Nov 4, 2025 - Abstract #abs25-4096; 5156; Pres time: Dec 8, 2025; 06:00 PM - 08:00 PM; Location: OCCC - West Halls B3-B4; "Background : BCL-2 inhibitors like venetoclax have demonstrated encouraging remission rates whencombined with fludarabine, cytarabine, idarubicin, and G-CSF (FLAG-IDA), enabling more patients toproceed to stem cell transplantation (SCT)...All patients received a busulfan/fludarabine-basedconditioning regimen and received post-transplant cyclophosphamide and tacrolimus as GVHDprophylaxis...Two patients relapsed following HSCT at a median time of 203 days (196-209days), including the patient undergoing SCT with positive MRD and a patient with very high risk acutemegakaryoblastic leukemia who relapsed following cessation of a folate receptor 1-targeted antibodydrug conjugate (STRO-002) due to adverse effects...One patient experienced CMV reactivation 28 daysafter SCT with peak level of 338 IU/mL requiring IV foscarnet, 1 patient experienced MRSA bacteremia onday 10 following SCT treated with appropriate antibiotic coverage, and 1 patient experienceddisseminated..."
Clinical • Acute Graft versus Host Disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Hepatology • Immunology • Infectious Disease • Leukemia • Pediatrics • Transplantation • CD8 • FOLR1
|
|
Irtiza Sheikh1; Reeja Raj1; Olayinka Okeleji1; Samanta Catueno1; Aaron Fan1; David McCall1; Amber Gibson1; Miriam Garcia1; Jeremy Connors1; Michael Roth1; Cesar Nunez1; Demetrios Petropoulos1; Branko Cuglievan1; Priti Tewari1
|